Metastatic cancer remains a formidable challenge in oncology, often evading conventional treatments due to its systemic nature and resistance mechanisms. This study introduces an innovative nanotherapeutic strategy that integrates photothermal therapy (PTT) with hypoxia-activated chemotherapy to achieve comprehensive tumor suppression. The core of this approach lies in the use of semiconducting polymer nanoparticles (SPNs), specifically PDPSe NPs, engineered for superior near-infrared absorption and high photothermal conversion efficiency. These nanoparticles are combined with tirapazamine (TPZ), a bioreductive prodrug selectively activated under hypoxic conditions commonly found in solid tumors.
The PDPSe NPs were synthesized through Stille coupling, resulting in a conjugated polymer with extended π-electron systems, which enabled redshifted absorption to 808 nm—ideal for deep-tissue penetration. The nanoparticles exhibited excellent colloidal stability, spherical morphology (~58 nm by DLS), and a remarkable mass extinction coefficient of 44.9 L g⁻¹ cm⁻¹ at 808 nm, along with a photothermal conversion efficiency of 62.5%. In vitro assays confirmed low dark toxicity, while laser irradiation induced significant cytotoxicity in 4T1 breast cancer cells, with an IC₅₀ of 10.05 mg mL⁻¹. TPZ alone showed moderate efficacy (IC₅₀ = 6.07 mg mL⁻¹), but when combined with PTT, the synergistic effect drastically enhanced cell death, reducing viability to an IC₅₀ of just 5.81 mg mL⁻¹.
In vivo evaluations using a bilateral tumor model demonstrated the therapeutic potential of this dual-modality approach. Primary tumors were treated with intratumoral injection of PDPSe NPs followed by 808 nm laser irradiation (1.5 W cm⁻², 10 min). Real-time infrared imaging revealed rapid temperature elevation to over 60 °C at the primary site, confirming effective photothermal ablation. Notably, distant tumors—simulating metastases—showed marked growth inhibition even without direct laser exposure. Tumor volume analysis indicated that the PDPSe NPs + laser + TPZ group achieved the most profound suppression, with minimal residual tumor burden upon resection.
Mechanistically, this outcome was linked to immune remodeling. Immunofluorescence staining revealed increased infiltration of CD8⁺ T cells and M1 macrophages in both primary and distant tumors. Flow cytometry of spleen tissues demonstrated a significant rise in effector T cells (CD4⁺ and CD8⁺) and elevated levels of key cytokines including IFN-γ, TNF-α, and IL-4, indicating robust systemic immune activation.NF-κB p65 Antibody manufacturer Conversely, immunosuppressive populations such as Tregs and MDSCs were markedly reduced, particularly in the combination therapy group.Slug Antibody manufacturer H&E and TUNEL staining confirmed extensive apoptosis and tissue destruction in the treated tumors, with no signs of organ damage or abnormal serum biochemistry.PMID:34839289
These findings highlight a powerful synergy between PTT and hypoxia-targeted chemotherapy. The photothermal ablation not only destroys local tumors but also releases tumor antigens, triggering adaptive immunity. Meanwhile, TPZ enhances the antitumor effect in hypoxic regions and contributes to immune modulation. Together, they transform the tumor microenvironment into a pro-inflammatory state capable of eradicating disseminated disease. This multimodal strategy offers a promising solution for treating metastatic cancers, overcoming limitations of single-modality therapies. Future directions include optimizing nanoparticle delivery and exploring NIR-II excitation for deeper tumor targeting.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com